Jaqueline de Azevêdo Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jaqueline de Azevêdo Silva has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Thays Maria Costa de Lucena
Laboratory of Human Genetics and Molecular Biology, Department of Genetics, Center of Biosciences, Federal University of Pernambuco, Recife, Pernambuco, Brazil; Molecular Biology Sector, Keizo Asami Institute, Federal University of Pernambuco, Recife, Pernambuco, Brazil; Laboratory of Immunoparasitology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil
6 shared publicationsMaria Eduarda de Albuquerque Borborema
Laboratory of Human Genetics and Molecular Biology, Genetics Department, Federal University of Pernambuco, Recife, Pernambuco, Brazil; Laboratory of Immunopathology Keizo Asami, Federal University of Pernambuco, Recife, Pernambuco, Brazil
5 shared publications- Sergio Crovella
Laboratory of Animal Research Center (LARC), Qatar University, Doha, Qatar
5 shared publications Michelle Christiane da Silva Rabello
Laboratory of Immunoparasitology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil
3 shared publications- Alexandre Domingues Barbosa
Rheumatology Division, Clinical Hospital of Federal University of Pernambuco, Recife 50670-901, PE, Brazil
2 shared publications Ariane Fernandes da Silva Santos
Laboratory of Human Genetics and Molecular Biology, Department of Genetics, Center for Biosciences, Federal University of Pernambuco, Recife, Brazil
2 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5548
A Bone-Protective Role for IFN-γ? Evidence from Genetic Association and Osteoblast Functional Assays in Postmenopausal Osteoporosis
Osteoporosis (OP) is a complex disease in which several immune-related genes have been identified as contributing to susceptibility and disease progression. Despite efforts to achieve functional validation, many of these genes, such as interferon-gamma (IFNG), remain the subject of unresolved mechanisms. The present study aimed to examine whether the IFNG -1616 (G>A, rs2069705) polymorphism was associated with postmenopausal OP. A total of 251 OP patients and 115 healthy controls were genotyped to assess the association between the IFNG -1616 (G>A, rs2069705) polymorphism and osteoporosis. To further investigate the biological role of IFN-γ in bone metabolism, human SaOs-2 osteosarcoma cells were treated with recombinant IFN-γ (2 and 100 U/mL), and calcification and cell viability were evaluated using Alizarin Red staining and the MTT assay, respectively. We found that the IFNG rs2069705 G allele was associated with an increased risk of OP (OR = 1.45, 95% CI = 1.03–2.05, p = 0.03). Furthermore, serum IFN-γ levels did not differ significantly between genotype groups. In SaOs-2 cells, IFN-γ (2 U/mL) significantly increased viability (p = 0.017) and enhanced calcification in a dose-dependent manner. The IFNG rs2069705 G allele may confer susceptibility to postmenopausal OP. IFN-γ promotes osteoblast viability and mineralization at low concentrations, suggesting a potential anabolic role that warrants further investigation in human primary osteoblasts.
- 19 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5548
Open AccessA Bone-Protective Role for IFN-γ? Evidence from Genetic Association and Osteoblast Functional Assays in Postmenopausal Osteoporosis
Osteoporosis (OP) is a complex disease in which several immune-related genes have been identified as contributing to susceptibility and disease progression. Despite efforts to achieve functional validation, many of these genes, such as interferon-gamma (IFNG), remain the subject of unresolved mechanisms. The present study aimed to examine whether the IFNG -1616 (G>A, rs2069705) polymorphism was associated with postmenopausal OP. A total of 251 OP patients and 115 healthy controls were genotyped to assess the association between the IFNG -1616 (G>A, rs2069705) polymorphism and osteoporosis. To further investigate the biological role of IFN-γ in bone metabolism, human SaOs-2 osteosarcoma cells were treated with recombinant IFN-γ (2 and 100 U/mL), and calcification and cell viability were evaluated using Alizarin Red staining and the MTT assay, respectively. We found that the IFNG rs2069705 G allele was associated with an increased risk of OP (OR = 1.45, 95% CI = 1.03–2.05, p = 0.03). Furthermore, serum IFN-γ levels did not differ significantly between genotype groups. In SaOs-2 cells, IFN-γ (2 U/mL) significantly increased viability (p = 0.017) and enhanced calcification in a dose-dependent manner. The IFNG rs2069705 G allele may confer susceptibility to postmenopausal OP. IFN-γ promotes osteoblast viability and mineralization at low concentrations, suggesting a potential anabolic role that warrants further investigation in human primary osteoblasts.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 7247751
Xeroderma Pigmentosum Monozygotic Twins: Same Mutation Divergent Clinical Outcomes
Xeroderma pigmentosum (XP) is a rare monogenic disorder characterized by UV sensitivity and skin cancer predisposition, caused by mutations in the NER pathway or the gene encoding DNA polymerase eta (Pol η ), which acts in translesion synthesis (TLS). Although XP is a monogenic disorder, differences in clinical severity may occur even between monozygotic twins. Here, we present monozygotic twins (M3 and M6) with the XP variant (XP‐V) displaying differences in clinical severity despite sharing similar environments and habits. Using whole genome sequencing (WGS), we evaluated their mutational burden and the impact of therapeutic strategies. Our results confirmed their kinship and the expected presence of the same POLH mutation in both patients. The somatic mutation profiles showed that Patient M3 harbored a significantly higher number of somatic mutations ( p ≤ 0.0001), including the exclusive detection of the ID8 signature. Despite these differences, the mutational spectrum remained remarkably consistent between twins (cosine similarity > 0.98). In addition, as one of the patients was submitted to cisplatin (CDDP) therapy, we confirmed in vitro the impact of CDDP on the cell cycle of TLS‐deficient cells. Therefore, the analyses of the genome sequences of these twin XP‐V patients revealed that during their lifetime endogenous DNA damage and therapeutic treatments may lead to high levels of mutations and phenotype divergency in their genome.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 7247751
Open AccessXeroderma Pigmentosum Monozygotic Twins: Same Mutation Divergent Clinical Outcomes
Xeroderma pigmentosum (XP) is a rare monogenic disorder characterized by UV sensitivity and skin cancer predisposition, caused by mutations in the NER pathway or the gene encoding DNA polymerase eta (Pol η ), which acts in translesion synthesis (TLS). Although XP is a monogenic disorder, differences in clinical severity may occur even between monozygotic twins. Here, we present monozygotic twins (M3 and M6) with the XP variant (XP‐V) displaying differences in clinical severity despite sharing similar environments and habits. Using whole genome sequencing (WGS), we evaluated their mutational burden and the impact of therapeutic strategies. Our results confirmed their kinship and the expected presence of the same POLH mutation in both patients. The somatic mutation profiles showed that Patient M3 harbored a significantly higher number of somatic mutations ( p ≤ 0.0001), including the exclusive detection of the ID8 signature. Despite these differences, the mutational spectrum remained remarkably consistent between twins (cosine similarity > 0.98). In addition, as one of the patients was submitted to cisplatin (CDDP) therapy, we confirmed in vitro the impact of CDDP on the cell cycle of TLS‐deficient cells. Therefore, the analyses of the genome sequences of these twin XP‐V patients revealed that during their lifetime endogenous DNA damage and therapeutic treatments may lead to high levels of mutations and phenotype divergency in their genome.
- 2 July 2025
- Published by Elsevier in Tuberculosis
- Vol. 154, 102672
Efficient cell model for assessing inflammatory responsive genes in Mycobacterium tuberculosis and SARS-CoV-2 co-infection
- 2 July 2025
- Published by Elsevier in Tuberculosis
- Vol. 154, 102672
Efficient cell model for assessing inflammatory responsive genes in Mycobacterium tuberculosis and SARS-CoV-2 co-infection
- Open Access
SARS-CoV-2 and Mycobacterium tuberculosis co-infection in vitro
In less than a year, SARS-CoV-2 (SARS2) has managed to displace Mycobacterium tuberculosis (Mtb) as the leading cause of death worldwide due to a single infectious agent. Both pathogens affect the respiratory tract, mainly the lungs. However, the impact that a possible Mtb + SARS2 co-infection can have on the host response is still unknown. Herein we propose (depict) a rigorous system to evaluate the complex interaction between the two infections in vitro in a lung epithelial cell line (A549). Overall, the process includes eight steps: (I) Mtb culture, (II) cell maintenance, (III) preparation of viral stocks, (IV) determination of infectious titers, (V) Mtb and SARS2 co-infection, (VI) determination of intracellular bacterial load, (VII) SARS2 viability test, and (VIII) decontamination of supernatants. This comprehensive protocol will allow experimentalists to study the pathogenesis of co-infection in vitro , and facilitate collaborative work in the literature.
Open AccessSARS-CoV-2 and Mycobacterium tuberculosis co-infection in vitro
In less than a year, SARS-CoV-2 (SARS2) has managed to displace Mycobacterium tuberculosis (Mtb) as the leading cause of death worldwide due to a single infectious agent. Both pathogens affect the respiratory tract, mainly the lungs. However, the impact that a possible Mtb + SARS2 co-infection can have on the host response is still unknown. Herein we propose (depict) a rigorous system to evaluate the complex interaction between the two infections in vitro in a lung epithelial cell line (A549). Overall, the process includes eight steps: (I) Mtb culture, (II) cell maintenance, (III) preparation of viral stocks, (IV) determination of infectious titers, (V) Mtb and SARS2 co-infection, (VI) determination of intracellular bacterial load, (VII) SARS2 viability test, and (VIII) decontamination of supernatants. This comprehensive protocol will allow experimentalists to study the pathogenesis of co-infection in vitro , and facilitate collaborative work in the literature.
- 20 February 2024
- Published by Elsevier in Tuberculosis
- Vol. 146, 102497
Steroid immune responsive gene regulation in Mycobacterium tuberculosis infection in vitro
- 20 February 2024
- Published by Elsevier in Tuberculosis
- Vol. 146, 102497
Steroid immune responsive gene regulation in Mycobacterium tuberculosis infection in vitro
- 22 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-6
Pathogen recognition pathway gene variants and inflammasome sensors gene expression in tuberculosis patients under treatment
Background Several epidemiological studies have suggested that genetic variations in encoding pattern recognition receptors (PRRs) genes such as Toll Like Receptors (TLRs) and their signaling products, may influence the susceptibility, severity and outcome of tuberculosis (TB). After sensing a pathogen, the cell responds producing an inflammatory response, to restrain the pathogen’s successful course of infection. Herein we assessed single nucleotide polymorphisms (SNP) and gene expression from pathogen recognition and inflammasome pathways in Brazilian TB patients. Methods and results For genetic association analysis we included MYD88 and TLR4, PRRs sensing proteins. Allele distribution for MYD88 rs6853 (A > G) and TLR4 rs7873784 (C > G) presented conserved among the tested samples with statistically differential distribution in TB patients versus controls. However, when testing according to sample ethnicity (African or Caucasian-derived individuals) we identified that the rs6853 G/G genotype was associated with a lower susceptibility to TB in Caucasian population. Meanwhile, the rs7873784 G/G genotype was associated with a higher TB susceptibility in Afro-descendant ethnicity individuals. We also aimed to verify MYD88 and the inflammasome genes NLRP1 and NLRC4 expression in order to connect to active TB and/or clinical aspects. Conclusions We identified that inflammasome gene expression in TB patients under treatment display a similar pattern as in healthy controls, indicating that TB treatment impairs NLRP1 inflammasome activation.
- 22 January 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-6
Pathogen recognition pathway gene variants and inflammasome sensors gene expression in tuberculosis patients under treatment
Background Several epidemiological studies have suggested that genetic variations in encoding pattern recognition receptors (PRRs) genes such as Toll Like Receptors (TLRs) and their signaling products, may influence the susceptibility, severity and outcome of tuberculosis (TB). After sensing a pathogen, the cell responds producing an inflammatory response, to restrain the pathogen’s successful course of infection. Herein we assessed single nucleotide polymorphisms (SNP) and gene expression from pathogen recognition and inflammasome pathways in Brazilian TB patients. Methods and results For genetic association analysis we included MYD88 and TLR4, PRRs sensing proteins. Allele distribution for MYD88 rs6853 (A > G) and TLR4 rs7873784 (C > G) presented conserved among the tested samples with statistically differential distribution in TB patients versus controls. However, when testing according to sample ethnicity (African or Caucasian-derived individuals) we identified that the rs6853 G/G genotype was associated with a lower susceptibility to TB in Caucasian population. Meanwhile, the rs7873784 G/G genotype was associated with a higher TB susceptibility in Afro-descendant ethnicity individuals. We also aimed to verify MYD88 and the inflammasome genes NLRP1 and NLRC4 expression in order to connect to active TB and/or clinical aspects. Conclusions We identified that inflammasome gene expression in TB patients under treatment display a similar pattern as in healthy controls, indicating that TB treatment impairs NLRP1 inflammasome activation.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Genetics and Molecular Biology
- Vol. 46 (1 suppl 2) , e20220158
Vitamin D and estrogen steroid hormones and their immunogenetic roles in Infectious respiratory (TB and COVID-19) diseases
The role of steroid hormones against infectious diseases has been extensively studied. From immunomodulatory action to direct inhibition of microorganism growth, hormones D3 (VD3) and 17β-estradiol (E2), and the genetic pathways modulated by them, are key targets for a better understanding pathogenesis of infectious respiratory diseases (IRD) such as tuberculosis (TB) and the coronavirus disease-19 (COVID-19). Currently, the world faces two major public health problems, the outbreak of COVID-19, accounting for more than 6 million so far, and TB, more than 1 million deaths per year. Both, although resulting from different pathogens, the Mtb and the SARS-CoV-2, respectively, are considered serious and epidemic. TB and COVID-19 present similar infection rates between men and women, however the number of complications and deaths resulting from the two infections is higher in men when compared to women in childbearing age, which may indicate a role of the sex hormone E2 in the context of these diseases. E2 and VD3 act upon key gene pathways as important immunomodulatory players and supporting molecules in IRDs. This review summarizes the main roles of these hormones (VD3 and E2) in modulating immune and inflammatory responses and their relationship with TB and COVID-19.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Genetics and Molecular Biology
- Vol. 46 (1 suppl 2) , e20220158
Open AccessVitamin D and estrogen steroid hormones and their immunogenetic roles in Infectious respiratory (TB and COVID-19) diseases
The role of steroid hormones against infectious diseases has been extensively studied. From immunomodulatory action to direct inhibition of microorganism growth, hormones D3 (VD3) and 17β-estradiol (E2), and the genetic pathways modulated by them, are key targets for a better understanding pathogenesis of infectious respiratory diseases (IRD) such as tuberculosis (TB) and the coronavirus disease-19 (COVID-19). Currently, the world faces two major public health problems, the outbreak of COVID-19, accounting for more than 6 million so far, and TB, more than 1 million deaths per year. Both, although resulting from different pathogens, the Mtb and the SARS-CoV-2, respectively, are considered serious and epidemic. TB and COVID-19 present similar infection rates between men and women, however the number of complications and deaths resulting from the two infections is higher in men when compared to women in childbearing age, which may indicate a role of the sex hormone E2 in the context of these diseases. E2 and VD3 act upon key gene pathways as important immunomodulatory players and supporting molecules in IRDs. This review summarizes the main roles of these hormones (VD3 and E2) in modulating immune and inflammatory responses and their relationship with TB and COVID-19.
- 12 May 2022
- Published by Wiley in International Journal of Immunogenetics
- Vol. 49 (3) , 181-192
Differential distribution of vitamin D receptor (VDR) gene variants and its expression in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disorder that displays an important genetic background. Vitamin D3 (VD3) through its receptor (VDR) plays an important immunomodulatory role in autoimmune misbalance, being capable of modulating immune responses. Genetic alterations in VDR gene may contribute to an altered risk in SLE development and clinical manifestations. We investigated VDR SNPs (single nucleotide polymorphisms) frequencies in 128 SLE patients and 138 healthy controls (HC) and mRNA differential expression in 29 patients and 17 HC regarding SLE susceptibility as well as clinical features. We observed that rs11168268 G allele (OR = 1.55, p = .01) and G/G genotype (OR = 2.69, p = .008) were associated with increased SLE susceptibility. The rs2248098 G allele and A/G and G/G genotypes were associated to lower SLE susceptibility (OR = 0.66, p = .01; OR = 0.46, p = .01; OR = 0.44, p = .02, respectively). Regarding clinical features, we observed lower risk for: rs11168268 A/G genotype and nephritis (OR = 0.31, p = .01); rs4760648 T/T genotype and photosensitivity (OR = 0.24, p = .02); rs1540339 T/T genotype and antibody anti‐dsDNA (OR = 0.19, p = .015); rs3890733 T/T genotype and serositis (OR = 0.10, p = .01). We identified a significant downregulation in VDR expression levels when compared patients and controls overall (p = 1.04e–7), in Cdx‐2 A/G and G/G (p = .008 and p = .014, respectively) and in patients with nephritis (p = .016)Our results suggested that VDR SNPs influence upon SLE susceptibility and in particular clinical features, acting on mRNA expression in SLE patients overall and the ones with nephritis.
- 12 May 2022
- Published by Wiley in International Journal of Immunogenetics
- Vol. 49 (3) , 181-192
Differential distribution of vitamin D receptor (VDR) gene variants and its expression in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disorder that displays an important genetic background. Vitamin D3 (VD3) through its receptor (VDR) plays an important immunomodulatory role in autoimmune misbalance, being capable of modulating immune responses. Genetic alterations in VDR gene may contribute to an altered risk in SLE development and clinical manifestations. We investigated VDR SNPs (single nucleotide polymorphisms) frequencies in 128 SLE patients and 138 healthy controls (HC) and mRNA differential expression in 29 patients and 17 HC regarding SLE susceptibility as well as clinical features. We observed that rs11168268 G allele (OR = 1.55, p = .01) and G/G genotype (OR = 2.69, p = .008) were associated with increased SLE susceptibility. The rs2248098 G allele and A/G and G/G genotypes were associated to lower SLE susceptibility (OR = 0.66, p = .01; OR = 0.46, p = .01; OR = 0.44, p = .02, respectively). Regarding clinical features, we observed lower risk for: rs11168268 A/G genotype and nephritis (OR = 0.31, p = .01); rs4760648 T/T genotype and photosensitivity (OR = 0.24, p = .02); rs1540339 T/T genotype and antibody anti‐dsDNA (OR = 0.19, p = .015); rs3890733 T/T genotype and serositis (OR = 0.10, p = .01). We identified a significant downregulation in VDR expression levels when compared patients and controls overall (p = 1.04e–7), in Cdx‐2 A/G and G/G (p = .008 and p = .014, respectively) and in patients with nephritis (p = .016)Our results suggested that VDR SNPs influence upon SLE susceptibility and in particular clinical features, acting on mRNA expression in SLE patients overall and the ones with nephritis.